Codeine

Introduction Overview

Generic Name

Codeine

Brand Name

Various (available as single ingredient and combination products)

Dosage Form

Oral tablet, oral solution, combination tablets/solutions with other analgesics or cold/flu medications

Drug Class

Antitussives; Opioids (narcotic analgesics)

Pharmacokinetics

Absorption:
Codeine is well absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations usually occurring within 1 to 2 hours. The bioavailability is around 50-60%, attributed to significant first-pass metabolism in the liver. Factors such as gastrointestinal motility, food intake, and hepatic enzyme activity can influence absorption rates and plasma levels. In clinical settings, oral administration is preferred due to ease of use and predictable absorption in most patients.

Distribution:
Codeine is distributed widely throughout the body, including crossing the blood-brain barrier and the placenta. It is moderately bound to plasma proteins, approximately 7-25%, which allows for efficient CNS penetration to exert its analgesic and antitussive effects. The volume of distribution averages 3 to 4 L/kg, indicating extensive tissue distribution. Codeine also enters breast milk, which necessitates caution during breastfeeding.

Metabolism:
Codeine undergoes extensive hepatic metabolism primarily by cytochrome P450 2D6 (CYP2D6) into morphine, which is largely responsible for its analgesic effect. Other metabolic pathways include O-demethylation to morphine, N-demethylation to norcodeine, and conjugation to codeine-6-glucuronide. Genetic polymorphisms highly affect CYP2D6 activity, resulting in variable and sometimes dangerous plasma levels of morphine, particularly in ultra-rapid metabolizers who can experience toxicity even at standard doses. Furthermore, this metabolic variability underscores the need for personalized dosing and monitoring.

Elimination:
The elimination half-life of codeine is approximately 3 hours, though this can vary depending on metabolism and renal function. Codeine and its metabolites are primarily excreted renally, with around 90% recovered in the urine as a mixture of unchanged drug and metabolites, including morphine and conjugates. Renal impairment can lead to accumulation of codeine and active metabolites, increasing the risk of adverse effects. Clinicians should adjust doses or monitor drug levels carefully in patients with renal dysfunction.

Dosage Forms

Available Dosage Forms:
-Codeine is available as oral tablets (immediate release and controlled release in some markets).
-Oral solution formulations exist for pediatric and adult use.
-Combination products include codeine with acetaminophen, aspirin, or other analgesics, as well as codeine combined with antihistamines and decongestants in cough and cold remedies.

Dosages for Adults and Adolescents:
-For pain management, typical initial oral doses range from 15 to 60 mg every 4 hours as needed.
-The maximum recommended daily dose is 360 mg to limit toxicity and adverse effects.
-Doses should always be individualized based on pain severity, patient response, and risk of addiction or adverse effects.
-Medical guidelines advise cautious use with close monitoring for respiratory depression within the first 24-72 hours of therapy and following any dose increase.

Specific Patient Populations:
-Codeine is contraindicated in children under 18 years old due to risks of respiratory depression.
-Dose adjustments or avoidance are necessary in patients with hepatic or renal impairment due to changes in metabolism and elimination.
-Use during pregnancy is discouraged because of potential neonatal opioid dependence and withdrawal; risk of life-threatening respiratory depression in the neonate.
-Breastfeeding is contraindicated while taking codeine because it can pass into breast milk causing sedation or life-threatening effects in infants.
-Caution is required in elderly, malnourished, or debilitated patients who may be at higher risk for adverse effects.
-Patients with respiratory conditions, such as asthma or COPD, require careful dosing and monitoring.

Mechanism Of Action

Codeine is a naturally occurring opiate and acts primarily as a prodrug. After oral administration, codeine is metabolized in the liver via the cytochrome P450 enzyme CYP2D6 into morphine, which binds with high affinity to mu-opioid receptors (MOR) located throughout the central nervous system (CNS) and peripheral tissues. The analgesic and antitussive effects of codeine are mainly mediated through MOR activation. This receptor activation inhibits adenylate cyclase activity, reducing cyclic AMP levels, and modulates ion channel activity—resulting in hyperpolarization of neurons.

At the cellular level, codeine-derived morphine binding to MOR inhibits release of neurotransmitters such as substance P, glutamate, and calcitonin gene-related peptide (CGRP) from nociceptive neurons in the dorsal horn of the spinal cord. This dampens transmission of pain signals to higher brain centers. Additionally, MOR activation in the brainstem suppresses the cough reflex, explaining codeine's antitussive properties.

Compared to morphine, codeine has weaker affinity for opioid receptors. The analgesic potency is largely dependent on the extent of metabolic conversion to morphine, which varies widely due to CYP2D6 genetic polymorphisms among individuals. Ultra-rapid metabolizers convert more codeine to morphine, increasing analgesic effects and risk of toxicity, while poor metabolizers experience reduced efficacy. This metabolic variability is clinically significant and guides individualized dosing and contraindications.

Research studies and clinical trials confirm that codeine’s therapeutic effects arise from this opioid receptor-mediated mechanism, and adverse effects such as respiratory depression, sedation, and constipation result from the same pathways. Unlike some other opioids, codeine has limited intrinsic activity at kappa and delta opioid receptors, which contributes to a lower risk of euphoria and dependence compared to stronger opioids, although misuse potential remains high.

Pharmacological Actions

Acts as a weak mu-opioid receptor agonist providing analgesic effects
Metabolized to morphine, which has stronger opioid receptor binding and analgesic potency
Suppresses cough reflex via central nervous system action on cough centers in the brainstem
Produces sedation and CNS depression through opioid receptor activation
Modulates neurotransmitter release in pain pathways, reducing nociceptive signal transmission
Causes gastrointestinal motility reduction leading to constipation
Has antitussive, analgesic, and mild sedative properties
Minimal affinity for kappa and delta opioid receptors compared to stronger opioids
Potential for respiratory depression due to slowing of brainstem respiratory centers
Exerts effects that can cause miosis (pinpoint pupils), a hallmark of opioid action
Induces histamine release in some patients, potentially causing pruritus or rash
Can cause mood alterations including euphoria or dysphoria depending on dosage and patient
Produces dose-dependent physical dependence and withdrawal symptoms upon cessation
Metabolic variability leads to differences in clinical response and risk of toxicity
Interacts with serotonergic pathways, potentially contributing to serotonin syndrome when combined with certain drugs

Therapeutic Or Clinical Uses

Management of mild to moderately severe pain where opioid treatment is appropriate
Adjunct treatment when non-opioid analgesics are inadequate
Suppression of non-productive cough refractory to other treatments
Used in combination formulations for cold and flu symptom relief including cough and minor pain
Relief of tension headache pain as part of combination analgesics
Used in palliative care to manage mild pain and cough symptoms
Occasional use in dental and postoperative mild pain situations
Treatment of cough in clinical cases where cough suppression is necessary
As an alternative opioid analgesic for patients intolerant to stronger opioids
Short-term management of pain where benefits outweigh risks of opioid exposure
As part of multimodal analgesia in chronic pain management under strict supervision
Off-label use in some countries for treatment of diarrhea due to opioid-induced constipation effects
Occasional use in combination with other agents for treatment of cold and allergy symptoms

Side Or Adverse Effects

Drowsiness and sedation
Nausea and vomiting
Constipation due to reduced gastrointestinal motility
Itching and mild skin rash related to histamine release
Respiratory depression, which can be severe and life-threatening especially in sensitive populations
Dizziness and light-headedness increasing fall risk
Pinpoint pupils (miosis), indicative of opioid effect
Confusion, agitation, hallucinations, or unusual behavior in some cases
Urinary retention and difficulty urinating
Hypotension and bradycardia in rare cases
Increased risk of seizures, particularly with overdose or in predisposed individuals
Risk of physical dependence, tolerance, and withdrawal symptoms upon abrupt discontinuation
Serotonin syndrome when combined with serotonergic drugs, presenting with agitation, fever, muscle stiffness
Anaphylaxis and severe allergic reactions in rare instances
Potential neonatal respiratory depression and withdrawal if used during pregnancy

Precautions

Avoid use in patients with severe respiratory diseases such as asthma or COPD without close monitoring
Exercise caution in patients with hepatic or renal impairment due to altered metabolism and excretion
Do not use in children under 18 years of age due to risk of fatal respiratory depression
Screen for CYP2D6 ultra-rapid metabolizer status if possible or consider alternative analgesics
Monitor for signs of opioid addiction, abuse, and misuse; use lowest effective dose for shortest duration
Avoid in patients with gastrointestinal obstruction or severe constipation
Use caution in patients with head injury or increased intracranial pressure to avoid masking neurologic symptoms
Avoid concomitant use with other CNS depressants and alcohol to reduce risk of profound sedation and respiratory depression
Caution in patients with a history of substance use disorder or mental illness
Monitor for serotonin syndrome if combined with serotonergic drugs
Use carefully in elderly, malnourished, or debilitated patients due to increased risk of adverse effects
Pregnant women should avoid codeine due to neonatal opioid dependence and withdrawal risk
Do not breastfeed while taking codeine because of transmission to infant and risk of fatal sedation
Educate patients about safe storage to prevent accidental ingestion or misuse
Do not abruptly discontinue after long-term use to avoid withdrawal symptoms; taper gradually under supervision

Warnings

Codeine can cause life-threatening respiratory depression, especially in children and ultra-rapid metabolizers
Use during pregnancy may cause neonatal opioid withdrawal syndrome with life-threatening symptoms
Concomitant use with alcohol or other CNS depressants increases risk of sedation, respiratory depression, coma, and death
Potential for addiction, abuse, and misuse leading to overdose and death
Contraindicated in patients with severe asthma, respiratory depression, gastrointestinal obstruction, or hypersensitivity
Do not use in children under 18 years old due to high risk of fatal respiratory depression
Overdose can induce severe muscle weakness, coma, cold clammy skin, slow breathing, and miosis
Risk of serotonin syndrome when combined with serotonergic medications
Can cause profound sedation and impair physical/mental abilities required for hazardous tasks
Not recommended for chronic non-cancer pain due to limited evidence and high risk of harm
Rapid metabolism to morphine in some individuals may unexpectedly increase opioid effects and toxicity
Risk of neonatal harm if taken during labor and delivery
Potential for serious allergic reactions requiring emergency treatment
Life-threatening respiratory depression has been reported in post-operative pediatric patients receiving codeine after tonsillectomy/adenoidectomy
Maintain vigilance when prescribing and dispensing codeine due to high abuse potential and regulatory concerns

Contraindication

Known hypersensitivity or allergy to codeine or other opioids
Severe respiratory depression or acute asthma attacks
Obstruction of the gastrointestinal tract including paralytic ileus
Patients younger than 18 years old
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs
Severe hepatic impairment where metabolism is significantly compromised
Known or suspected ultra-rapid metabolizers of CYP2D6 with risk of morphine toxicity
Patients with known or suspected opioid addiction or history of substance abuse when risk outweighs benefits
Concomitant use with other CNS depressants without appropriate monitoring
Use during labor and delivery where opioid-induced respiratory depression of the neonate is a concern
Patients with paralytic ileus or severe constipation
Avoid breastfeeding due to risk of opioid transmission to infant
Patients with severe head injury or increased intracranial pressure where CNS depressants would obscure neurologic assessment
Patients with frequent or severe asthma attacks or hyperventilation
Patients with significant hypotension and bradycardia that could worsen with opioid effects

Drug Interactions

Additive CNS and respiratory depression with other opioids, benzodiazepines, and sedatives such as diazepam, alprazolam, lorazepam
Increased risk of serotonin syndrome with concomitant use of serotonergic drugs including SSRIs, SNRIs, triptans, and MAO inhibitors
Potential reduced efficacy with CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) decreasing morphine formation
Enhanced opioid effects with CYP2D6 inducers potentially increasing morphine levels
Increased risk of sedation and respiratory depression with alcohol or other CNS depressants
Interactions with anticonvulsants (e.g., phenytoin) and antifungal agents affecting metabolism
Additive hypotensive effects with antihypertensives and diuretics
Potential interactions with anticholinergic drugs exacerbating constipation and urinary retention
Increased sedation with muscle relaxants and antipsychotics
CYP3A4 inhibitors may raise plasma codeine concentrations; e.g., HIV protease inhibitors
Colchicine may increase CNS depression when combined
Opioid antagonists (e.g., naloxone) reverse the therapeutic effects of codeine
Careful monitoring advised when combining with herbal supplements, particularly St. John's Wort which may alter metabolism
Potential interaction with antiarrhythmics altering cardiac conduction enhanced by opioids
Opioids can interfere with hypothalamic-pituitary-adrenal axis affecting multiple drug responses

Preparations Of The Drug

Single ingredient codeine sulfate oral tablets available in strengths ranging from 15 mg to 60 mg
Oral solutions of codeine sulfate, appropriate for pediatric and adult dosing
Combination tablets containing codeine with acetaminophen (e.g., Tylenol #3) with varying codeine content (e.g., 30 mg) paired with fixed acetaminophen doses
Codeine combined with aspirin in various analgesic formulations
Cough syrups containing codeine combined with antihistamines and decongestants for cold and flu symptom relief
Extended-release tablets and capsules (available in some countries) for chronic pain management
Combination formulations for headache relief with additional agents such as caffeine or sedatives
Codeine analogues and prodrugs such as dihydrocodeine in related preparations
Injection forms available in hospital settings but less commonly used compared to oral forms
Controlled-substance scheduling in most countries, requiring prescription and regulated dispensing
Formulations intended for oral use only, with clear labeling to prevent accidental pediatric ingestion
Some combination products include codeine and promethazine for cough and allergy symptom management
Packages often include patient information highlighting risks of addiction and instructions for safe storage and disposal
Formulated with flavoring agents in liquid preparations to facilitate pediatric compliance
Formulations supplied under various brand names globally, tailored to regional regulatory control